BRD4 and hematopoietic and lymphoid system neoplasm: AZD5153, in clinical development, binds simultaneously to both bromodomains of BRD4 and has been confirmed to regulate MYC and HEXIM1 transcription, indicating its efficacy as an oral BET/BRD4 inhibitor for blood cancer [94].